头颈癌分子和血液生物标志物、治疗和结果临床研究平台 (HEAT)
头颈癌分子和血液临床研究平台
Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients.
研究概览
详细说明
The advent of checkpoint inhibitors has changed the treatment landscape in SCCHN and new treatment sequences have entered clinical practice.
More in-depth knowledge of tumor biomarkers are important measures for optimization of treatment strategies in SCCHN. In addition to this, investigations may involve other assessments, which will be explored separately, such as molecular testing. These tests are then linked to the core data set and will allow to associate such measures with outcomes. This concept is flexible and allows for rapid integration of contemporary research questions in a timely manner.
Furthermore, insights into the treatment reality for recurrent/metastatic salivary gland carcinoma and other rare tumor entities (SNUC, etc.) are urgently needed, as there is currently no established standard of care.
The monoclonal antibody cetuximab in combination with platinum and fluorouracil (EXTREME) has been the standard of care for recurrent or metastatic (r/m) SCCHN for over a decade.1 Recently, the immune checkpoint inhibitors (CPIs) nivolumab and pembrolizumab have changed the therapeutic landscape of patients with r/m SCCHN. Nivolumab is considered as therapeutic standard after failure of platinum-based therapy based on the results of the phase III Checkmate-141 trial.2 In addition, pembrolizumab has become the new standard in the first-line setting in combination with platinum/fluorouracil chemotherapy or as monotherapy for patients with programmed cell death ligand 1 (PD-L1) positive tumors based on the data from the phase III Keynote-048 trial.3 Moreover, cetuximab in combination with platinum and docetaxel (TPEx) has emerged as a less toxic alternative to the EXTREME regimen.4 Due to the shifting first-line treatment landscape, data to guide contemporary 2nd line therapy are scarce and the optimal treatment sequence remains vague.2,5,6 The implementation of biomarkers and selection of patients in a real-world setting are areas of academic interest. In addition, the assessment of treatment outcomes in rare entities are underrepresented in pivotal trials, and as a matter of fact, may be completely excluded. However, broad labels permit the use of novel agents, but a larger body of evidence is needed to substantiate such treatment choices. HEAT seeks to address these questions by inclusion of a real-world patient population and continuous assessment of oncological outcomes by means of a core clinical data set implemented into HEAT.
Overall, HEAT is a study platform, which continuously assesses clinical outcomes and modularly integrates additional measures to enable rapid answers to research questions.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Project Manager
- 电话号码:+49 (0)30 814534431
- 邮箱:kht-register@aio-studien-ggmbh.de
学习地点
-
-
-
Essen、德国、45147
- 尚未招聘
- Universitätsklinikum Essen
-
接触:
- Michael Pogorzelski, Dr. med.
- 电话号码:+49 (0) 157 38 79 55 41
- 邮箱:Michael.Pogorzelski@uk-essen.de
-
Hanover、德国、30161
- 招聘中
- Onkologie/Studienzentrum am Raschplatz GbR
-
接触:
- Eyck von der Heyde, Dr. med.
- 电话号码:+49 (0) 511 86649985
- 邮箱:vdheyde@onkologie-am-raschplatz.de
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adult patients with histologically or cytologically confirmed malignancy of the head neck area including but not limited to
- squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx or larynx
- not amenable for curative treatment who receive palliative systemic treatment or best supportive care.
描述
Inclusion Criteria:
- Age ≥ 18 years
- Able to understand and willing to sign written informed consent
- Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)
- Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care
- Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving "best supportive care only": no later than six weeks after diagnosis/recurrence or metastatic disease
Exclusion Criteria: none
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_ONLY
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sociodemographic factors
大体时间:3 years
|
Highest level of education, Employment status, Current professional activity, Professional risk factors, Level of self-sufficiency, Care degree |
3 years
|
|
Treatments
大体时间:3 years
|
Types of local therapies (surgery, radiotherapy, radiochemotherapy), systemic therapy and therapeutic sequences |
3 years
|
|
Response rates
大体时间:3 years
|
Response rates |
3 years
|
|
Treatment decision
大体时间:3 years
|
Physician-reported parameters affecting treatment decision |
3 years
|
|
Progression-free survival
大体时间:3 years
|
Progression-free survival |
3 years
|
|
Time-to-treatment-failure
大体时间:3 years
|
Time-to-treatment-failure |
3 years
|
|
Overall survival
大体时间:3 years
|
Overall survival |
3 years
|
合作者和调查者
调查人员
- 研究主任:Victor Grünwald, Prof. Dr.、Universitätsklinikum Essen
- 首席研究员:Michael Pogorzelski, Dr.、Universitätsklinikum Essen
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.